Table 1.

Current treatment recommendations in different gastric cancer guidelines (5, 6, 8, 9).

Country/stage	Clinical stage IA	Clinical stage IB-IIIC
United States	Endoscopic or surgical resection	Resection with D2 lymph node dissection. Preferred strategy: perioperative chemotherapy (with fluorouracil and cisplatin, or fluoropyrimidine and oxaliplatin, or ECF/EOF/EOC/ECC, guideline was published in 2017, before results of the FLOT4-AIO).
Europe	Endoscopic or surgical resection	Resection with D2 lymph node dissection. Preferred strategy: perioperative chemotherapy with a platinum/fluoropyrimidine combination. Other postoperative pathways: postoperative chemoradiotherapy or postoperative chemotherapy
Asia	Endoscopic or surgical (with D1/D1+ lymph node dissection)	Resection with D2 lymph node dissection. Postoperative course depending on pathology stage: I: observation II/III: postoperative chemotherapy with S-1 monotherapy or oxaliplatin plus capecitabine*

*Guidelines in Asia differ slightly. In Japan, S-1 monotherapy is recommended for pathological stage II and capecitabine plus oxaliplatin for stage III. In Korea, both options are offered as treatment option. In China, combined chemotherapy with platinum and fluorouracil preferred (not exceeding 6 months) and for fragile patients fluorouracil monotherapy (not exceeding 12 months).